{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093941","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.448324+00:00","generated_at":"2026-05-31T11:06:08.738383+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AVITA Medical Q2 commercial revenue record $15.1M (+29%); FY24 guide $68-70M","bullets":["Commercial revenue $15.1M (+29% YoY); gross margin 86.2% (up 500 bps).","Net loss $15.4M ($0.60 loss per share) vs $10.4M loss ($0.41) in Q2 2023.","RECELL GO PMA approved May 29; RECELL GO mini submitted June 28, FDA decision by Dec 27.","Exclusive distribution deal with Regenity for dermal matrix; 510(k) clearance expected Q4 2024.","Q3 2024 revenue guidance $19-20M (40-48% YoY growth); FY24 guide revised to $68-70M (37-41% growth)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093941","json":"https://secwatch.observer/filing/0000950170-24-093941.json","markdown":"https://secwatch.observer/filing/0000950170-24-093941.md","text":"https://secwatch.observer/filing/0000950170-24-093941.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024093941/0000950170-24-093941-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024093941/rcel-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:06:08.738383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}